CITrials Clinical Work Helps Merck Wins Alzheimer's Label Claim for Insomnia Drug Belsomra
A leading clinical research facility, CITrials clinical work has helped Merck to get FDA approval for a new use of its insomnia drug Belsomra, treating sleep disruption in people with mild-to-moderate Alzheimer's disease. The approval for this label is based on clinical trials done in CITrials. Belsomra's activity in Alzheimer's was demonstrated in a 285-subject, four-week sleep study, published in Alzheimer's & Dementia, which found significant improvements compared to placebo in total sleep time (TST) and wake after sleep onset...
View full press release